These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 16033831)

  • 1. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
    Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
    Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
    Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
    Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
    Leppä S; Saarto T; Vehmanen L; Blomqvist C; Elomaa I
    Breast Cancer Res Treat; 2005 Mar; 90(2):117-25. PubMed ID: 15803358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
    Redondo P; Lloret P; Idoate M; Inoges S
    Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
    Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
    Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
    Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
    Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of malignant melanoma.
    Vihinen P; Koskivuo I; Syrjänen K; Tervahartiala T; Sorsa T; Pyrhönen S
    Melanoma Res; 2008 Aug; 18(4):268-73. PubMed ID: 18626311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
    Sliwowska I; Kopczyński Z
    Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
    Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
    Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
    Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
    Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
    Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma.
    Hayasaka A; Suzuki N; Fujimoto N; Iwama S; Fukuyama E; Kanda Y; Saisho H
    Hepatology; 1996 Nov; 24(5):1058-62. PubMed ID: 8903375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma.
    Väisänen AH; Kallioinen M; Turpeenniemi-Hujanen T
    Hum Pathol; 2008 Mar; 39(3):377-85. PubMed ID: 18187184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
    Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases in mild and severe temporomandibular joint internal derangement synovial fluid.
    Srinivas R; Sorsa T; Tjäderhane L; Niemi E; Raustia A; Pernu H; Teronen O; Salo T
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 May; 91(5):517-25. PubMed ID: 11346728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
    Riedel F; Götte K; Schwalb J; Hörmann K
    Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis].
    Fiedorczyk M; Klimiuk PA; Sierakowski S; Domysławska I; Chwiećko J
    Przegl Lek; 2005; 62(12):1321-4. PubMed ID: 16786739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.